Aprea Therapeutics reports positive results in Phase 1 ACESOT-1051 trial.

Aprea Therapeutics reported that 3 out of 4 patients achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies at the 100 mg APR-1051 dose level. Disease stabilization was observed in patients with tumors harboring mutations relevant to WEE1 kinase inhibition. Dose escalation continues, with patients now enrolling in the 150 mg cohort. Preliminary results from the ACESOT-1051 trial will be featured in a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.